Venous Vascular Closure

0
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

C
CordisFL - Miami Lakes
2 programs
MYNX CONTROLTM VENOUS Vascular Closure DeviceN/A1 trial
MYNX CONTROL™ Venous Vascular Closure Device 6F-12FN/A1 trial
Active Trials
NCT07246902Recruiting300Est. Aug 2026
NCT05554471Completed352Est. Jul 2023

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
CordisMYNX CONTROLTM VENOUS Vascular Closure Device
CordisMYNX CONTROL™ Venous Vascular Closure Device 6F-12F

Clinical Trials (2)

Total enrollment: 652 patients across 2 trials

NCT07246902CordisMYNX CONTROLTM VENOUS Vascular Closure Device

Mobilization and Outcomes After Venous Closure

Start: Nov 2025Est. completion: Aug 2026300 patients
N/ARecruiting
NCT05554471CordisMYNX CONTROL™ Venous Vascular Closure Device 6F-12F

Evaluation of Safety and Efficacy of the Mynx Control Venous Vascular Closure Device 6F-12F vs Manual Compression

Start: Aug 2022Est. completion: Jul 2023352 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 652 patients
1 companies competing in this space